Argatroban915

A total of 418 patients with acute HIT (n = 189) or HITTS (n = 229) were prospectively treated with argatroban in study ARG-915 or its extension (together referred to as "Argatroban-915") (Lewis et al., 2003). The mean argatroban dose was 1.8 mg/kg/min, and the mean duration of therapy was 6 days. Comparisons were

(A) Study Day

FIGURE 5 Time to first event for the composite endpoint through day 37 in study ARG-911. Significant differences in favor of argatroban therapy were detected in (A) the HlT study arm (argatroban group, n = 160; historical controls, n = 147) and (B) the HIT with thrombosis study arm (argatroban group, n = 144; historical controls, n = 46). Abbreviations: ARG-911, argatro-ban-911; HIT, heparin-induced thrombocytopenia. Source: Data from Lewis et al., 2001.

FIGURE 5 Time to first event for the composite endpoint through day 37 in study ARG-911. Significant differences in favor of argatroban therapy were detected in (A) the HlT study arm (argatroban group, n = 160; historical controls, n = 147) and (B) the HIT with thrombosis study arm (argatroban group, n = 144; historical controls, n = 46). Abbreviations: ARG-911, argatro-ban-911; HIT, heparin-induced thrombocytopenia. Source: Data from Lewis et al., 2001.

made with 185 historical controls with acute HIT with or without thrombosis (obtained from ARG-911).

0 0

Post a comment